Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.
Janus kinase inhibitors: between prescription authorization and reimbursability
Iannone F.;
2023-01-01
Abstract
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
REUMA4_2023_ING_01_EDITOR_1627_161-166 (1).pdf
accesso aperto
Descrizione: articolo principale
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
582.98 kB
Formato
Adobe PDF
|
582.98 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
